These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28806603)

  • 1. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
    Overwijk WW
    Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
    Grenier JM; Yeung ST; Khanna KM
    Front Immunol; 2018; 9():610. PubMed ID: 29623082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of cancer immunotherapeutic strategies.
    Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
    Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
    Fecek RJ; Storkus WJ
    Immunotherapy; 2016 Oct; 8(10):1205-18. PubMed ID: 27605069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy as an Option for Cancer Treatment.
    Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to checkpoint inhibitors and cancer immunotherapy.
    Sharpe AH
    Immunol Rev; 2017 Mar; 276(1):5-8. PubMed ID: 28258698
    [No Abstract]   [Full Text] [Related]  

  • 13. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade.
    Bersanelli M; Leonetti A; Buti S
    Immunotherapy; 2017 Nov; 9(14):1127-1131. PubMed ID: 29067883
    [No Abstract]   [Full Text] [Related]  

  • 15. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
    Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
    Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.
    Emerson DA; Redmond WL
    BioDrugs; 2018 Jun; 32(3):221-231. PubMed ID: 29637478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.
    Xie Y; Xiang Y; Sheng J; Zhang D; Yao X; Yang Y; Zhang X
    J Immunol Res; 2018; 2018():8740976. PubMed ID: 29785403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel vaccines for glioblastoma: clinical update and perspective.
    Winograd EK; Ciesielski MJ; Fenstermaker RA
    Immunotherapy; 2016 Nov; 8(11):1293-1308. PubMed ID: 27993092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.